Vericel (VCEL) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings or view top-rated stocks.

4 brokers have issued 1 year price objectives for Vericel's stock. Their VCEL share price forecasts range from $34.00 to $42.00. On average, they expect the company's share price to reach $37.25 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price.
View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts.

Vericel's stock was trading at $26.34 at the start of the year. Since then, VCEL stock has increased by 25.0% and is now trading at $32.93.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our VCEL earnings forecast.

Vericel Co. (NASDAQ:VCEL) posted its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.10. The biotechnology company earned $52.70 million during the quarter, compared to the consensus estimate of $52.95 million. Vericel had a negative trailing twelve-month return on equity of 9.26% and a negative net margin of 10.11%. Vericel's quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.09 earnings per share.

ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), RiverFront Dynamic US Flex-Cap ETF (RFFC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Vericel issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $184.00 million-$192.00 million, compared to the consensus revenue estimate of $186.54 million.

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.66%), Brown Capital Management LLC (14.81%), RTW Investments LP (6.92%), State Street Corp (5.74%), Conestoga Capital Advisors LLC (5.01%) and Fisher Asset Management LLC (3.66%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends.

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCEL stock can currently be purchased for approximately $32.93.

Vericel (NASDAQ:VCEL) has a market capitalization of $1.57 billion and generates $163.70 million in revenue each year. The biotechnology company earns $-16,710,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

The company employs 281 workers across the globe.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (617) 588-5555, via email at ir@vcel.com, or via fax at 617-588-5554.